Cargando…

Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis

PURPOSE: Immune checkpoint inhibitors (ICI) and targeted small-molecule drugs are mainstay elements of lung cancer chemotherapy. However, they are associated with development of pneumonitis, a rare, but potentially life-threatening event. We analyzed lung cancer patients treated with ICI to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Jongheon, Kim, Hyae Young, Kim, Dong-Gil, Park, Seog Yun, Ko, A Ra, Han, Ji-Youn, Kim, Heung Tae, Lee, Jin Soo, Lee, Youngjoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812016/ https://www.ncbi.nlm.nih.gov/pubmed/32777877 http://dx.doi.org/10.4143/crt.2020.543

Ejemplares similares

Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
por: Park, Changhee, et al.
Publicado: (2019)

Chronic immune checkpoint inhibitor pneumonitis
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
por: Kim, Hye Sook, et al.
Publicado: (2023)

Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment
por: Kang, Tae Heung, et al.
Publicado: (2020)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Pneumonitis after Stereotactic Thoracic Radioimmunotherapy with Checkpoint Inhibitors: Exploration of the Dose–Volume–Effect Correlation
por: Kraus, Kim Melanie, et al.
Publicado: (2022)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
por: Serzan, Michael T, et al.
Publicado: (2020)

Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis
por: Davis Puente, Andrea, et al.
Publicado: (2023)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
por: Yun, Tak, et al.
Publicado: (2011)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
por: Choi, Yu-ra, et al.
Publicado: (2022)

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
por: Yun, Tak, et al.
Publicado: (2016)

Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study
por: Jang, Jeong Yun, et al.
Publicado: (2021)

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
por: Chuzi, Sarah, et al.
Publicado: (2017)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
por: Zhu, Shicong, et al.
Publicado: (2020)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
por: Ando, Hiroyuki, et al.
Publicado: (2021)

Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
por: Miao, Kang, et al.
Publicado: (2021)

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
por: Zhou, Chengzhi, et al.
Publicado: (2022)

The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports
por: Mojsak, Damian, et al.
Publicado: (2022)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
por: Wang, Wenxian, et al.
Publicado: (2022)

A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry
por: Faucheux, Andrew, et al.
Publicado: (2023)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

Safety of sequential immune checkpoint inhibitors after prior immune therapy
por: Awidi, Muhammad, et al.
Publicado: (2022)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic
por: Chang, Hsu-Liang, et al.
Publicado: (2020)

Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
por: Uchida, Yasuki, et al.
Publicado: (2022)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2022)

Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
por: Tan, Peixin, et al.
Publicado: (2023)

Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
por: Huang, Jie, et al.
Publicado: (2023)

Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis
por: Cui, Pengfei, et al.
Publicado: (2023)

Radiation recall pneumonitis from immune checkpoint inhibitors after extra pulmonary radiation
por: Kao, Leslie E., et al.
Publicado: (2023)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
por: Bi, Jianping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uf7mjeb1iu9md8864ap058t0u3